Side-by-side · Research reference

AdipotidevsKPV

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BAnimal-StrongAUTO-DRAFTED13/39 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

KPV

α-MSH C-terminal · Anti-inflammatory

200–500 mcgDaily doseDalle-Pang 2024

AnimalEvidence levelDalle-Pang 2024

HoursHalf-life (est)

SQ / oral / topical · Local · Daily or 2-3×/week

01Mechanism of Action

Parameter

Adipotide

KPV

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

No melanocortin receptor binding

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024

Antibody development

—

02Dosage Protocols

Parameter

Adipotide

KPV

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

—

Route

Intravenous (systemic injection)

—

Frequency

Not specified in available data

Daily or 2–3× per week

Evidence basis

Preclinical animal models only

Animal-strong + emerging clinical data in IBDDalle-Pang 2024

Human data

None — no clinical trials reported

—

Standard dose

—

200–500 mcg / day SQ or oralDalle-Pang 2024

Lower / starter dose

—

100 mcg / day

Duration

—

4–8 weeks per cycle

Reconstitution

—

Bacteriostatic water (SQ form)

Timing

—

No specific time; often taken with / before meals (oral)

Half-life

—

Hours (estimated; rapid tissue uptake)

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

KPV

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

04Side Effects & Safety

Parameter

Adipotide

KPV

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

—

Injection site reaction

—

Mild irritation

GI symptoms

—

Rare nausea (oral form)

Pigmentation

—

None (unlike full α-MSH)Dalle-Pang 2024

Long-term safety

—

Limited human data

Pregnancy / OB

—

Avoid — insufficient data

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

KPV

·Pregnancy / breastfeeding

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

KPV

·Active autoimmune disease (theoretical)

05Administration Protocol

Parameter

Adipotide

KPV

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Add 1 mL bacteriostatic water to vial per labelling.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

Morning preferred; oral form taken with / before meals.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G insulin syringe (SQ form).

06Stack Synergy

Adipotide

— no documented stacks

KPV

+ BPC-157

Strong

View BPC-157 →

KPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.

KPV: 200–500 mcg oral · daily
BPC-157: 250–500 mcg oral or SQ · daily
Primary benefit: Combined anti-inflammation + mucosal repair for gut conditions

Dalle-Pang 2024 Sikiric 2018